Aldeyra Therapeutics’s $72.1 Million follow-on offering


Gunderson Dettmer advised Aldeyra Therapeutics, Inc. on a follow-on public offering of 5,250,000 shares at the price to the public of $13.75 per share for a total of $72,187,500 in aggregate gross proceeds.

Citigroup acted as lead bookrunning manager for the offering. Cantor Fitzgerald & Co. also acted as a bookrunning manager. Laidlaw & Company (UK) Ltd., Janney Montgomery Scott and JonesTrading acted as co-managers.

Aldeyra, which trades on The Nasdaq Capital Market under the ticker symbol “ALDX,” is a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases.

Gunderson Dettmer advised Aldeyra Therapeutics with a team including Jay Hachigian (Picture), Keith Scherer, Albert Vanderlaan, Naomi Smith and John Maciejewski.

Involved fees earner: Jay Hachigian – Gunderson Dettmer; Keith Scherer – Gunderson Dettmer; Albert Vanderlaan – Gunderson Dettmer; Naomi Smith – Gunderson Dettmer; John Maciejewski – Gunderson Dettmer;

Law Firms: Gunderson Dettmer;

Clients: Aldeyra Therapeutics;

Author: Ambrogio Visconti